MIXiii BIOMED 2017 - May 23-25, Tel Aviv
The Federation of Israeli Chambers of Commerce invites partners of international chambers of commerce and trade organizations to participate in Israel' 16th National Life Sciences & Technology Week, to be held May 23-25, 2017 in Tel-Aviv, Israel.
As the leading event of Israel’s life science industry, MIXiii-BIOMED has positioned itself throughout the years as the main annual meeting place for players of Israel’s healthcare industry with their colleagues from around the globe. The conference attracts visitors worldwide who come to explore the various innovations, and experience firsthand the entrepreneurial spirit which is a basis of Israel’s vibrant life science community.
BioMed former successful conferences have hosted over 6,000 senior executives, scientists, and engineers, including approximately 1,000 participants from over 45 countries and with a total of 4,500 one-on-one meetings.
This year’s conference is co-organized by leading international healthcare institutions with the objective of exposing industry participants to leaders and experts, allow local and global attendees to mix and exchange information, knowledge and ideas.
Exhibitor Profile includes Bio Products, Development and Enabling Technologies, Agro Bio, Laboratory Equipment and Instruments, Financial Services for the Industry, Medical Devices, Drugs, Indications, Gene Therapy, Vaccines, Computer Aided Drug Discovery & Bio informatics (including Functional Genomics), Nano Biotechnology & Bio-Electronics, Technical Services for the Industry.
For MIXiii BIOMED program - click here
The event is orginized by Israel Advanced Technologies Industry (IATI) and Kenes Exhibitions in cooperation with leading organizations and companies in the field of Healthcare and Life Science.
We invite representatives of regional and domestic chambers of commerce ,as well as trade promotion organizations to contact us for further information and assistance in the registration process.
Please fill-in the hereunder form and we will revert to you in due course.